human mpo

AZD5904 is a potent and irreversible human Myeloperoxidase (MPO) inhibitor(IC50 of 140 nM and has similar potency in mouse and rat).

MPO-IN-10 is an orally active, selective, and irreversible inhibitor of myeloperoxidase (MPO), exhibiting an IC50 of 0.080 μM for human MPO. It demonstrates higher selectivity for extracellular MPO over intracellular MPO found in neutrophils. MPO-IN-10 can be utilized in the research of inflammation-related diseases such as vascular disorders.

Aminopyridine 2 is an irreversible, selective, and orally active myeloperoxidase (MPO) inhibitor with an IC50 of 0.16 μM and a Ki of 24 μM for human MPO. It is utilized in research involving chronic inflammatory diseases.

2-chloro Palmitic acid is a monochlorinated form of palmitic acid . It is produced in a myeloperoxidase (MPO) and time-dependent manner in neutrophils stimulated by phorbol 12-myristate 13-acetate . 2-chloro Palmitic acid (10 μM) induces neutrophil extracellular trap (NET) formation (NETosis) in human neutrophils, increasing DNA release from neutrophils, colocalization of MPO with extracellular DNA (ecDNA), and trapping of E. coli. It increases COX-2 protein levels in human coronary artery endothelial cells (HCAECs) when used at a concentration of 50 μM and increases production of P-selectin, von Willebrand factor, and angiopoietin-2 in HCAECs, as well as neutrophil and platelet adherence, when used at a concentration of 10 μM. 2-chloro Palmitic acid (10-50 μM) also induces apoptosis in THP-1 cells and primary human monocytes and increases caspase-3 activity in THP-1 cells.

Aseanostatin P5 inhibits myeloperoxidase (MPO) release from human polymorphonuclear leukocytes.

HLF1-11, derived from human lactoferrin, serves as a broad-spectrum antimicrobial agent. It not only inhibits human MPO (myeloperoxidase) activity but also influences GM-CSF (granulocyte-macrophage colony-stimulating factor)-driven monocyte differentiation into macrophages, thereby augmenting immune responses [1] [2].

PMX-53, a macrocyclic complement 5a (C5a) peptidomimetic and C5a receptor antagonist (IC50 = 0.3 µM), effectively inhibits the C5a-induced secretion of myeloperoxidase (MPO) in isolated human polymorphonuclear leukocytes (PMNs). Administered orally at 10 mg/kg, PMX-53 mitigates vascular leakage, PMN infiltration, and the production of TNF-α and IL-6 in a rat peritoneal Arthus reaction model. Additionally, in a 3-nitropropionic acid (3-NP)-induced Huntington's disease rat model, it alleviates body weight loss, anorexia, and striatal degeneration. Furthermore, at a dose of 3 mg/kg, PMX-53 decreases atherosclerotic lesion size and lipid content in ApoE-/- mice.

Myeloperoxidase, human white blood cells (MPO), is a peroxidase enzyme. It modulates oxidative stress by promoting the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), influencing the polarization of microglia and neutrophils and regulating inflammation-related signaling pathways. Myeloperoxidase, human white blood cells also exhibits antibacterial activity.